Navigation Links
Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
Date:11/5/2007

- Early study data from the two lowest dose groups show dose-dependent PSA

declines to date in all patients -

- Conference call to be held today at 8:30 A.M. Eastern time -

SAN FRANCISCO, Nov. 5 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that its selective androgen receptor modulator, MDV3100, to date has reduced serum levels of prostate specific antigen (PSA), a marker of tumor growth, in the six patients enrolled in the first two dose groups of its ongoing Phase 1-2 trial in hormone refractory prostate cancer. PSA declines were seen in a dose-dependent manner in these patients. In the lowest dose group, after two months of treatment PSA levels declined 45 percent to 66 percent. PSA levels in the second lowest dose group declined 75 percent to 89 percent after the first month of treatment. MDV3100 has been well tolerated to date in both dose groups.

The ongoing Phase 1-2 trial is an open-label U.S. study enrolling prostate cancer patients who have failed standard hormonal therapies. The study is enrolling patients in up to seven dose groups of three patients each at escalating doses, with each group continuing treatment for at least three months barring any safety issues. The six patients enrolled to date comprise the two lowest dose groups, which to date have completed one and two months of treatment. Patient accrual for higher dose groups is ongoing. Once a maximum tolerated dose has been established, treatment at that dose level will be expanded to 20 patients. The study endpoints include safety, tolerability, pharmacokinetics, effects on serum PSA levels and disease progression.

"While these results are still preliminary, the declines
'/>"/>

SOURCE Medivation, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...wswire-FirstCall/ -- Ardea Biosciences, Inc.,(Nasd... "RDEA119, a Potent,and Highly Selective MEK1/2 In...SS) -- induced Chronic Colitis in Mice," was prese...ACG) 2008 Annual Meeting in Orlando,Florida. The ...dy of,RDEA119, the Company,s lead mitogen-activate...
(Date:10/6/2008)... /- Pharmasset, Inc.,(Nasda...., is joining the,Company as Vice President of Inv...Smith will be responsible for all investor relatio...ancial Officer Kurt,Leutzinger., Most recently, D...logy,Analyst at JPMorgan Securities, and has been ...
(Date:10/6/2008)... feature children, parents discussing clinical ...., Oct. 6 /PRNewswire-USNewswire/ -- From asthma a...dren saves lives and improves their,health and wel...es of,Health (NIH), "Children and Clinical Studies...h.gov ), offers parents and health,care providers ...
(Date:10/6/2008)...Oct. 6 /- Genaera,Corporati...econd Phase 1,clinical trial of trodusquemine (MSI...tment of type 2 diabetes and obesity. MSI-1436 is ...target that controls the function,of both the lept...ecrease,appetite. In the study, MSI-1436 was found...
Breaking Medicine Technology:Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 2Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 4Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4 New discovery leaves blood doping athletes scratching their heads 1667 1 New discovery leaves blood doping athletes scratching their heads 1667 2ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 472 1ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 472 2ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 472 3Genetic variation affects smoking cessation treatment 1663 1Genetic variation affects smoking cessation treatment 1663 2Moffitt Selects Microsofts Azyxxi to Help Drive Personalized Cancer Treatment 1661 1Moffitt Selects Microsofts Azyxxi to Help Drive Personalized Cancer Treatment 1661 2
...lyses To Be Presented --, SAN FRANCISCO, April 24,...oday announced that data from the Company,s Phase,...ease will be,presented for the first time in the U...s 59th Annual Meeting in Boston on Thursday,May 3... include new,data from both the mild and moderate ...
...., April 24, 2007 /PRNewswire/ -- Accera Inc.,anno...tudy of its,lead compound AC-1202 in Alzheimer,s d...g of the American Academy of Neurology (AAN) in,Bo...ent of the,program, the data will also be featured...ccera,s vice president of clinical development Dr....
Other Medicine Technology:Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting 2Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting 3Accera, Inc. to Present Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting 2
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...ering potentially fatal liver complications from c...y are given before a stem cell transplant// such a...tment. But chemotherapy causes five to 50 per cent...al complication called veno-occlusive disease (VOD...
... was observed that carbohydrates that originate in...ause arthritis.// Researchers from Harvard Medical...ed GAGs to the defense system in the body that cau...s been a mystery, this new finding may shed light ...
...American Journal of Clinical Nutrition it was obse...preventing the build up of plaque in the arteries ...h has shown antioxidant vitamins can protect again...ries. However, most studies have concentrated on p...
...evels of air pollution can trigger a heart attack ... for more than 24 hours. Researchers say that expo...lutants increased the risk of a heart attack by 40...who are most vulnerable are those already at risk ...
Other Medicine News:
14 cm - 5 1/2, 6.0 mm , for drill handles and hand drills.
Hudson Cranial Drill, complete, consisting of: brace; with extension piece and 4 burs
23 cm - 9, adult size, for skull thickness up to 12 mm.
Length-9 (229 mm) Tapered retractor blades.
Medicine Products: